[Form 4] ARGAN INC Insider Trading Activity

Rhea-AI Filing Summary

Peter W. Getsinger, a director of Argan, Inc. (AGX), sold 1,000 shares of the company's common stock on September 19, 2025, on the open market at an average price of $264.54 per share. After the sale, Getsinger beneficially owned 11,896 shares directly. The Form 4 was signed on September 23, 2025, and lists Getsinger's Edgartown, MA address and director status. No derivative transactions or amendments are reported and the filing indicates this was a routine open-market disposition executed at the stated price.

Insights

Financial Analyst

TL;DR: Insider sold a small portion of holdings: 1,000 shares at $264.54, leaving 11,896 shares—transaction appears routine, not unusually large.

The sale reduces Getsinger's direct stake but represents a modest sized disposition relative to typical institutional holdings for mid-cap issuers. The reported per-share price provides a concrete market execution level on 09/19/2025. With only non-derivative shares reported and no concurrent filings by other insiders, this Form 4 reflects a single open-market sale rather than an equity plan exercise or grant.

Corporate Governance Expert

TL;DR: Director sale disclosed properly on Form 4; filing shows compliance with Section 16 reporting requirements.

The Form 4 is complete for the reported non-derivative disposition and includes signature and explanatory note stating the sale occurred on the open market. There is no indication of Rule 10b5-1 plan usage on the face of this filing. The disclosure satisfies transparency expectations for director transactions but does not provide context on frequency or rationale for the sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Getsinger Peter W

(Last) (First) (Middle)

35 SNOWS POINT

(Street)

EDGARTOWN MA 02539

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARGAN INC [ AGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/19/2025		S		1,000(1)	D	$264.54	11,896	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On September 19, 2025, the Reporting Person sold 1,000 shares of the Issuer's common stock on the open market at a price of $264.54 per share.

	/s/ Peter W. Getsinger	09/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filed for AGX disclose?

The filing shows director Peter W. Getsinger sold 1,000 shares on 09/19/2025 at $264.54 per share, leaving 11,896 shares owned.

Was the transaction an open-market sale or part of an option exercise for AGX?

The Form 4 explanation states it was an open-market sale; no derivative transactions or option exercises are reported.

When was the Form 4 signed and filed for the AGX insider sale?

The signature on the Form 4 is dated 09/23/2025, with the transaction dated 09/19/2025.

How many shares does the reporting person own after the sale?

After the sale, the reporting person beneficially owned 11,896 shares of AGX common stock.

Does the Form 4 indicate use of a 10b5-1 trading plan for the sale?

The filing does not indicate that the transaction was made pursuant to a 10b5-1 plan; no such box is checked or plan referenced.